{
    "nctId": "NCT03306472",
    "briefTitle": "A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer",
    "officialTitle": "Randomised Phase II Clinical Trial PIONEER- A Pre-operative wIndOw Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole aloNE in Post-menopausal Patients With ER-positive Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 198,
    "primaryOutcomeMeasure": "Determination of change in tumour proliferation measured by Ki67 immunohistochemical (IHC) assessment (%) at baseline compared to Day 15 (+ \u22644 days).",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed breast adenocarcinoma\n* Postmenopausal women\n* Core biopsy confirmation of invasive carcinoma on core biopsy, \u2265T1c, either clinical NX or N0-N3\n* ER positive (Allred\u22653) and HER2 negative\n* 2 groups of patients are potentially eligible:\n\n  * Cohort A: Patients whose cancers have been deemed to be operable by the Multi-Disciplinary Team (MDT), with surgery planned for the next 2-6 weeks\n  * Cohort B: Patients with early or locoregionally advanced breast cancer planned for primary endocrine therapy, either in lieu of surgery or as neoadjuvant therapy prior to surgery- such patients must begin PIONEER trial therapy prior to starting any other endocrine therapy.\n* ECOG performance status of 0, 1 or 2\n* Adequate Liver, Renal and Bone marrow function, defined as:\n\n  * Adequate liver function where bilirubin is \u22641.5 x ULN\n  * Adequate renal function with serum creatinine \u2264 1.5 x ULN\n  * Adequate bone marrow function with ANC \u22651.0 x 10\\*9/L and Platelet count \u2265100 x 10\\*9/L\n* Written informed consent to participate in the trial and to donation of tissue\n\nExclusion Criteria:\n\n* History of hormone replacement therapy in the last 6 months\n* Previous treatment with Tamoxifen or an aromatase inhibitor in the last six months\n* Known hypersensitivity or contraindications to aromatase inhibitors or Megestrol acetate\n* Known allergy to lactose\n* Known to have a progestogen-containing intrauterine system in situ, unless removed prior to randomisation\n* Known metastatic disease on presentation\n* Recurrent breast cancer (patients with a new primary invasive breast cancer will be eligible to participate)\n* Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the trial, at the discretion of the investigator\n* Treatment with an investigational drug within 4 weeks before randomisation\n* Inability to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the trial medication\n* Inability to give informed consent",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}